Literature DB >> 10421645

Primary biliary cirrhosis once rare, now common in the United Kingdom?

O F James1, R Bhopal, D Howel, J Gray, A D Burt, J V Metcalf.   

Abstract

There is a widespread impression that the number of patients with the autoimmune liver disease primary biliary cirrhosis (PBC) is increasing, although its incidence and prevalence vary widely. Using thorough case-finding methods and rigorous definitions to assess changes in incidence and prevalence with time and to explore the symptomatology and mortality of the disease in a large group of unselected patients, we performed a descriptive epidemiological study of PBC in a well defined population over a fixed period of time using established diagnostic criteria and with clinical follow-up of all cases. In a population of 2.05 million in northern England 770 definite or probable PBC cases were identified. Prevalence rose from 201.9 per 10(6) in the adult population and 541. 4 per 10(6) women over 40 in 1987 to 334.6 per 10(6) adults and 939. 8 per 10(6) women over 40 in 1994. Incidence was 23 per 10(6) in 1987 and 32.2 per 10(6) in 1994. Three hundred patients died in median follow-up of 6.27 years (141 liver deaths); the standardized mortality ratio was 2.85. At presumed diagnosis, 60.9% had no symptoms of liver disease. By June 1994 62% of prevalent patients had liver symptoms. PBC is apparently increasing. It is still unclear whether this is because of a true increase, case finding, or increased disease awareness. The study draws attention to (1) high mortality from liver disease and non-liver-related causes even in patients initially with no liver symptoms and (2) apparently poor diagnostic awareness of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10421645     DOI: 10.1002/hep.510300213

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  57 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

2.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.

Authors:  M I Prince; A Chetwynd; W L Craig; J V Metcalf; O F W James
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

Review 3.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

4.  Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset.

Authors:  Michele Covelli; Ivana Favia; Mariapia Marrone; Florenzo Iannone; Antonia Gentile; Gaetano Lastilla; Giovanni Lapadula
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

Review 5.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

6.  Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis.

Authors:  A Jacoby; A Rannard; D Buck; N Bhala; J L Newton; O F W James; D E J Jones
Journal:  Gut       Date:  2005-06-16       Impact factor: 23.059

Review 7.  The immunology of primary biliary cirrhosis: the end of the beginning?

Authors:  J M Palmer; J A Kirby; D E J Jones
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Characterization of M2 antibodies in asymptomatic Chinese population.

Authors:  Xiao-Hua Jiang; Ren-Qian Zhong; Xiao-Yun Fan; Yin Hu; Feng An; Jian-Wen Sun; Xian-Tao Kong
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

9.  RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.

Authors:  Yan-Li Hao; Zhao-Lian Bian; Lin-Ling Ju; Yuan Liu; Gang Qin
Journal:  Dig Dis Sci       Date:  2019-08-03       Impact factor: 3.199

Review 10.  An update on the management of cholestatic liver diseases.

Authors:  Gautham Appanna; Yiannis Kallis
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.